127 related articles for article (PubMed ID: 32929128)
21. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
[TBL] [Abstract][Full Text] [Related]
22. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
[TBL] [Abstract][Full Text] [Related]
23. A subset of CD45+/CD19 - cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma.
Kim SM; Lee ST; Ryu KJ; Kim HJ; Kim SH; Ko YH; Kim WS; Kim SJ
Leuk Lymphoma; 2015; 56(11):3052-7. PubMed ID: 25739938
[TBL] [Abstract][Full Text] [Related]
24. Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy.
Alduailej H; Kanfar S; Bakhit K; Raslan H; Alsaber A; Bashawri L; Aldayel A; Alanezi K
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e560-e568. PubMed ID: 32600932
[TBL] [Abstract][Full Text] [Related]
25. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
26. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
27. Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
Zhang H; Chen Z; Neelapu SS; Romaguera J; McCarty N
Oncotarget; 2016 Mar; 7(12):14350-65. PubMed ID: 26885608
[TBL] [Abstract][Full Text] [Related]
28. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
[TBL] [Abstract][Full Text] [Related]
29. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
30. Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.
Tran L; Huitema AD; Vogel WV; Beijnen JH; Baars JW
J Oncol Pharm Pract; 2012 Dec; 18(4):417-20. PubMed ID: 22228555
[TBL] [Abstract][Full Text] [Related]
31. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Pavlasova G; Borsky M; Svobodova V; Oppelt J; Cerna K; Novotna J; Seda V; Fojtova M; Fajkus J; Brychtova Y; Doubek M; Pospisilova S; Mayer J; Mraz M
Leukemia; 2018 Sep; 32(9):2028-2031. PubMed ID: 30030508
[No Abstract] [Full Text] [Related]
32. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Matsuda I; Hirota S
Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711
[TBL] [Abstract][Full Text] [Related]
35. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
36. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
37. Kaposi's Sarcoma After Autologous Stem-Cell Transplantation and Rituximab Treatment.
Geller S; Dickson MA; Busam KJ; Myskowski PL
J Oncol Pract; 2018 Sep; 14(9):565-568. PubMed ID: 30044684
[No Abstract] [Full Text] [Related]
38. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy.
Ishiyama K; Takami A; Okumura H; Ozaki J; Shimadoi S; Yamanaka S; Nakao S
Int J Hematol; 2005 May; 81(4):319-22. PubMed ID: 15914363
[TBL] [Abstract][Full Text] [Related]
39. Mantle cell lymphoma mainly involving thoracic lesions: two case reports.
Kosaka M; Koizumi T; Fukushima T; Wada Y; Agatsuma T; Yokoyama T; Kanda S; Kubo K; Shimojo H; Horie S; Asano N
Intern Med; 2011; 50(14):1477-81. PubMed ID: 21757833
[TBL] [Abstract][Full Text] [Related]
40. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
